Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 1, 2007, Pages 92-96

  L'homme, Rafaëlla F A ^a   Dijkema, Tim ^a   Warris, Adilia ^a   van der Ven, Andre J A M ^a   Gibb, Diana M ^b   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Lamivudine; Nevirapine; Stavudine

Indexed keywords

GENERIC DRUG; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; PEDIMUNE BABY; PEDIMUNE JUNIOR; STAVUDINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONPARAMETRIC TEST; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSPENSION; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; HIV INFECTIONS; HUMANS; INFANT; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; PILOT PROJECTS; STAVUDINE; THERAPEUTIC EQUIVALENCY;

EID: 33845890515     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl445     Document Type: Article

References (9)

1. Palella FJJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
2. Gibb DM, Duong T, Tookey PA et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327: 1019.
3. Gogtay JA, Manek V, Nayak VG et al. A pharmacokinetic evaluation of lamivudine, stavudine and nevirapine given as a fixed dose combination pill versus the same three drugs given separately in healthy human volunteers. In: Programs and Abstracts of the Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, 2002. Abstract PL8.4, p. 11. Gardiner-Caldwell, UK.
4. Laurent C, Kouanfack C, Koulla-Shiro S et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: Open-label multicentre trial. Lancet 2004; 364: 29-34.
5. Narang VS, Lulla A, Malhotra G et al. A combined-formulation tablet of lamivudine/nevirapine/stavudine: Bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects. J Clin Pharmacol 2005; 45: 265-74.
6. Boerma JT, Stanecki KA, Newell ML et al. Monitoring the scale-up of antiretroviral therapy programmes: Methods to estimate coverage. Bull World Health Organ 2006; 84: 145-50.
7. L'homme RFA, Ellis J, Ewings F et al. Nevirapine concentrations in HIV-infected children treated with divided fixed dose combination tablets in Malawi and Zambia. In: Programs and Abstracts of the Seventh International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, 2006. Abstract 2, p. 3-4. Virology Education, Utrecht, Netherlands.
8. Verweij-van Wissen CP, Aarnoutse RE, Burger DM. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816: 121-9.
9. Hollanders RMW, van Ewijk-Beneken Kolmer EWJ, Burger DM et al. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000; 744: 65-71.